Back to Peptide Library
Investigational Small Molecule

SLU-PP-915

Pan-ERR Agonist • Oral Exercise-Mimetic Research

SLU-PP-915 is an orally active research compound that activates the estrogen-related receptors ERRα, ERRβ, and ERRγ. Mouse studies report changes in exercise-responsive genes and aerobic performance. It is a small molecule, not a peptide, and has no established human use.

Routes
Oral capsule
Compound type
Small molecule
Regulatory status
Not FDA approved
Last reviewed
At a glance

SLU-PP-915 Quick Reference

Evidence stage
Preclinical
Cell and mouse studies; no published human trial
Available format
Oral capsule
Oral activity studied in mice
Reported oral range
10–20 mg
Informal research-community range; not tested in people
Research target
ERRα / β / γ
Nuclear receptors regulating oxidative metabolism
Overview

What Is SLU-PP-915?

SLU-PP-915 is a synthetic small molecule in a series of estrogen-related receptor (ERR) agonists. These receptors regulate transcription of genes involved in mitochondrial function, fuel use, and adaptation to aerobic exercise. Despite its place in peptide catalogs, SLU-PP-915 is not a peptide.

Its boronic-acid-containing thiophene scaffold differs from SLU-PP-332. Published work reports improved metabolic stability and measurable oral activity in mice. That is a research advantage, not evidence of a safe or effective human capsule.

Mechanism

SLU-PP-915 Mechanism of Action

Pan-ERR activation

Cell assays show agonist activity across ERRα, ERRβ, and ERRγ. These are nuclear receptors, distinct from classical estrogen receptors.

Exercise-responsive transcription

Studies found increased expression of ERR-regulated genes, including PGC-1α, PDK4, and Ddit4, in cells or mouse tissues.

Oxidative metabolism

ERR signaling coordinates mitochondrial and fatty-acid-oxidation programs. Gene responses suggest pathway engagement; they do not establish the same adaptations as training in people.

Oral exposure

Unlike SLU-PP-332, SLU-PP-915 retained exercise-related activity after oral administration in mice when exposure was considered. Human absorption remains unknown.

Research findings

SLU-PP-915 Benefits

The reported outcomes come from laboratory and mouse models. No published human trial has shown that SLU-PP-915 improves exercise capacity, metabolism, or cardiovascular outcomes.

Current evidence level: preclinical

Aerobic performance in mice

Short mouse experiments reported greater running distance and duration after SLU-PP-915 exposure.

Ddit4 response

Mouse skeletal muscle showed an exercise-responsive gene signal that was sometimes comparable to treadmill running.

Oral activity

Mouse work found retained activity after oral administration at exposure-adjusted comparisons.

Cardiac research

In a pressure-overload mouse model, SLU-PP-915 improved selected heart-function and fibrosis measures.

Protocol planning

SLU-PP-915 Dosing Protocol

A 10–20 mg oral range is discussed in research communities, but published SLU-PP-915 dosing comes from animal experiments. No human schedule, cycle length, or route-specific safety profile has been established.

Reported oral range10–20 mg
Published population
Mice, not human volunteers.
Finding
Oral exposure produced exercise-related effects in a short preclinical study.
Duration
Short experiments; chronic safety is unknown.
Evidence status
The 10–20 mg range is informal and has not been validated in a human trial.
N=1 reports

SLU-PP-915 Community Experience

Published human experience is absent. Online anecdotes cannot establish identity, dose, efficacy, or safety for a retail product.

Why researchers are interested

  • Oral exposure. The newer scaffold addresses a practical limit of SLU-PP-332 in mouse research.
  • Distinct target. ERR activation studies examine exercise-responsive transcription beyond appetite pathways.
  • Comparator data. Published work directly compares SLU-PP-915 and SLU-PP-332 in preclinical models.

What remains uncertain

  • No human outcomes. Performance and gene-expression findings have not been replicated in people.
  • Product uncertainty. Retail capsules may not match the identity or exposure of study material.
  • No established regimen. Forum dose claims are anecdotes, not clinical evidence.
Stacking & synergy

SLU-PP-915 Stacking & Synergy

No human combination regimen has been validated. These pairings describe research questions and pathway overlap, not proven synergy.

SLU-PP-915 + exercise

One mouse study found stronger Ddit4 and mitochondrial gene responses alongside training. Human relevance is unknown.

SLU-PP-915 + O-304

SLU-PP-915 targets ERR signaling while O-304 activates AMPK. Their distinct metabolic pathways make this a research pairing; the combination has not been studied or shown to be beneficial.

SLU-PP-915 + MOTS-c

Both appear in metabolic research, but they act through different pathways. Their combination has not been clinically tested.

Safety notes

SLU-PP-915 Side Effects & Safety

There is no published human safety profile for SLU-PP-915. Short mouse experiments cannot rule out effects from prolonged ERR activation, different formulations, or higher exposure.

Absence of reported human adverse events reflects the absence of human trials, not proof of safety.

Known evidence limits

  • No controlled human adverse-event data.
  • No validated oral dose or exposure range in people.
  • No established long-term cardiac or metabolic safety profile.

Product-quality gaps

  • Retail identity and purity can vary by lot.
  • Capsule exposure cannot be inferred from mouse suspension studies.
  • Informal reports are not systematic safety surveillance.

The relevant research is preclinical; no frequency or severity of human side effects can be estimated.

SLU-PP-915 Precautions

Avoid unsupported assumptions
  • Do not treat animal outcomes as demonstrated human benefits.
  • Do not extrapolate an animal dose into a human regimen.
  • Do not infer safety in pregnancy, chronic illness, or with prescription medicines.
Interpret with care
  • Cardiac results came from a disease model in mice.
  • Gene-expression changes do not replace physical exercise.
  • Check whether product testing confirms the named compound.
Regulatory status: SLU-PP-915 is investigational and has no FDA-approved human use.
Final verdict

Peptide Protocols Verdict on SLU-PP-915

Editorial assessment for research and education. No human use protocol has been established.
Our opinionated opinion

SLU-PP-915 is a useful step for ERR research because it retains oral activity in mice and has direct comparison data against SLU-PP-332. The exercise and cardiac findings make the pathway worth following.

The practical case for people is still unproven. No human trial has established a benefit, dose, or safety window, and a retail capsule cannot be assumed to match the study formulation. We grade the science as promising but the real-world evidence as early.